ATE539746T1 - Zusammensetzung zur verbesserung von kognition und gedächtnis - Google Patents

Zusammensetzung zur verbesserung von kognition und gedächtnis

Info

Publication number
ATE539746T1
ATE539746T1 AT04727667T AT04727667T ATE539746T1 AT E539746 T1 ATE539746 T1 AT E539746T1 AT 04727667 T AT04727667 T AT 04727667T AT 04727667 T AT04727667 T AT 04727667T AT E539746 T1 ATE539746 T1 AT E539746T1
Authority
AT
Austria
Prior art keywords
memory
composition
improving cognition
cognition
improving
Prior art date
Application number
AT04727667T
Other languages
English (en)
Inventor
Nava Zisapel
Moshe Laudon
Original Assignee
Neurim Pharma 1991
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurim Pharma 1991 filed Critical Neurim Pharma 1991
Application granted granted Critical
Publication of ATE539746T1 publication Critical patent/ATE539746T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
AT04727667T 2003-04-29 2004-04-15 Zusammensetzung zur verbesserung von kognition und gedächtnis ATE539746T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL155666A IL155666A (en) 2003-04-29 2003-04-29 Insomnia treatment
PCT/IL2004/000330 WO2004096118A2 (en) 2003-04-29 2004-04-15 Composition for improving cognition and memory

Publications (1)

Publication Number Publication Date
ATE539746T1 true ATE539746T1 (de) 2012-01-15

Family

ID=33397641

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04727667T ATE539746T1 (de) 2003-04-29 2004-04-15 Zusammensetzung zur verbesserung von kognition und gedächtnis

Country Status (29)

Country Link
US (2) US8859593B2 (de)
EP (1) EP1620058B1 (de)
JP (2) JP4981440B2 (de)
KR (1) KR101136885B1 (de)
CN (1) CN1787820B (de)
AR (1) AR048370A1 (de)
AT (1) ATE539746T1 (de)
BR (1) BRPI0409935A (de)
CA (1) CA2521182C (de)
CL (1) CL2004000877A1 (de)
CY (1) CY1112689T1 (de)
DK (1) DK1620058T3 (de)
EA (1) EA008768B1 (de)
ES (1) ES2380364T3 (de)
HK (1) HK1087635A1 (de)
IL (1) IL155666A (de)
IS (1) IS8090A (de)
MX (1) MXPA05011590A (de)
NO (1) NO333015B1 (de)
NZ (1) NZ542724A (de)
PE (1) PE20050144A1 (de)
PL (1) PL1620058T3 (de)
PT (1) PT1620058E (de)
SI (1) SI1620058T1 (de)
TW (1) TWI340037B (de)
UA (1) UA87980C2 (de)
UY (1) UY28296A1 (de)
WO (1) WO2004096118A2 (de)
ZA (1) ZA200509508B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL155666A (en) * 2003-04-29 2013-12-31 Neurim Pharma 1991 Insomnia treatment
JP4993900B2 (ja) * 2005-11-28 2012-08-08 国立大学法人 東京医科歯科大学 記憶障害抑制剤
US8372876B2 (en) * 2007-03-06 2013-02-12 The University Of Houston System Method for improving memory in mammals
US8940326B2 (en) 2007-03-19 2015-01-27 Vita Sciences Llc Transdermal patch and method for delivery of vitamin B12
JP2010523714A (ja) 2007-04-12 2010-07-15 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 虚血／再灌流保護組成物および使用法
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
CA3159064A1 (en) 2012-01-26 2013-08-01 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
WO2014100292A1 (en) * 2012-12-18 2014-06-26 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
CA2975985A1 (fr) * 2015-02-04 2016-08-11 Soeur Josefa Menendez Systeme therapeutique transdermique contenant de la valentonine et son utilisation comme medicament
US10307398B2 (en) 2016-09-20 2019-06-04 Regents Of The University Of Minnesota Resuscitation composition and methods of making and using
PT3337462T (pt) 2016-10-31 2020-10-30 Neurim Pharmaceuticals 1991 Ltd Minicomprimidos de melatonina e método de fabrico dos mesmos
KR102499141B1 (ko) * 2016-10-31 2023-02-13 신신제약 주식회사 수면장애 치료용 경피흡수제제
US10849856B2 (en) 2016-10-31 2020-12-01 Neurim Pharmaceuticals Ltd. Melatonin mini-tablets and method of manufacturing the same

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US468017A (en) * 1892-02-02 Lock-case
US4506080A (en) 1983-07-01 1985-03-19 Nestec S. A. Preparation of serotonine and derivatives
US4765985A (en) * 1985-03-05 1988-08-23 Ciba-Geigy Corporation Devices and methods for treating memory impairment
US4680172A (en) * 1985-03-05 1987-07-14 Ciba-Geigy Corporation Devices and methods for treating memory impairment
US4965074A (en) * 1985-03-05 1990-10-23 Ciba-Geigy Corporation Method of treating memory impairment
ATE71287T1 (de) * 1986-06-13 1992-01-15 Alza Corp Aktivierung eines transdermalen drogenabgabesystems durch feuchtigkeit.
DE3645036A1 (de) 1986-11-18 1989-01-05 Forschungsgesellschaft Rauchen Nikotinhaltiges mittel
US5508039A (en) * 1991-10-18 1996-04-16 Alza Corporation Controlled transdermal administration of melatonin
WO1993014200A1 (en) * 1992-01-07 1993-07-22 Tsi Corporation Transgenic animal models for alzheimer's disease
SG41955A1 (en) * 1992-04-07 1997-08-15 Neurim Pharma 1991 Use of melatonin for the manufacture of a medicament for the treatment of benign prostatic hyperplasia
US5449683A (en) * 1992-10-01 1995-09-12 Massachussetts Institute Of Technology Methods of inducing sleep using melatonin
GB9310412D0 (en) 1993-05-20 1993-07-07 Danbiosyst Uk Nasal nicotine system
EP0708627B1 (de) * 1993-07-09 2000-02-02 Cygnus, Inc. Verfahren und vorrichtung für die transdermale oder transbuccale therapeutische verabreichung von nikotinsubstituten
JPH09512006A (ja) 1994-04-13 1997-12-02 チバ−ガイギー アクチェンゲゼルシャフト 時間的に調節された薬物供給システム
US5872101A (en) * 1995-01-06 1999-02-16 Sibia Neurosciences, Inc. Methods of treating neurodegenerative disorders using protease inhibitors
MD1716C2 (ro) 1995-02-01 2002-02-28 Neurim Pharmaceuticals (1991) Ltd. Utilizare a melatoninei pentru tratamentul pacienţilor dependenţi de benzodiazepine
US5696115A (en) * 1995-04-21 1997-12-09 Eli Lilly And Company Method for treating nicotine withdrawal
US5700828A (en) * 1995-12-07 1997-12-23 Life Resuscitation Technologies, Inc. Treatment or prevention of anoxic or ischemic brain injury with melatonin-containing compositions
US6183775B1 (en) * 1996-05-13 2001-02-06 Novartis Consumer Health S.A. Buccal delivery system
FR2762993B1 (fr) * 1997-05-06 1999-08-13 Inst Rech Biolog Sa Nouvelle utilisation de phospholipides d'origine animale en therapeutique et/ou dietetique
DE69819891T2 (de) * 1997-05-30 2004-08-26 Neurosearch A/S Spiro chinuclidin-derivate, ihre herstellung und verwendung
WO1999048489A2 (en) * 1998-03-25 1999-09-30 South Alabama Medical Science Foundation Melatonin for delaying the onset of alzheimer's disease and for treating or delaying the onset of other amyloidosis-related diseases/disorders
US6353015B1 (en) * 1998-08-26 2002-03-05 St. Elizabeth's Medical Center Method of treating neurodegenerative disorders
RU2134108C1 (ru) 1998-10-06 1999-08-10 Заславская Рина Михайловна Средство для лечения артериальной гипертонии, способ лечения артериальной гипертонии
FR2788982B1 (fr) * 1999-02-02 2002-08-02 Synthelabo Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique
CA2359640C (en) 1999-02-05 2008-11-18 Cipla Limited Topical sprays
US6353051B1 (en) * 1999-03-10 2002-03-05 E. I. Du Pont De Nemours And Company Top coating for synthetic leathers
HU227002B1 (en) 2000-01-05 2010-04-28 Neurim Pharma 1991 Use of melatonin in the manufacture of controlled release medicament for the prevention or treatment of symptoms of hypertension
EP2133078A1 (de) * 2000-03-03 2009-12-16 Eisai R&D Management Co., Ltd. Verwendung eines Cholinesterase-Hemmers für die Behandlung von kognitiven Beeinträchtigungen und/oder Demenz, die mit Gehirntumoren in Zusammenhang gebracht oder davon verursacht wird
DE10013712A1 (de) * 2000-03-20 2001-09-27 Nutrinova Gmbh Nikotinsalze mit verbessertem Geschmack, Verfahren zu ihrer Herstellung und ihre Verwendung
AU2001282873A1 (en) * 2000-08-18 2002-03-04 Pharmacia And Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
CA2440713A1 (en) 2001-03-26 2002-10-03 Smithkline Beecham Corporation Nicotine-containing oral dosage form
US20030051728A1 (en) 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
ATE276676T1 (de) * 2001-10-22 2004-10-15 Ivo Pera Zusammensetzung zur reduzierung oder entwöhnung von nikotinabhängigkeit
US7113651B2 (en) * 2002-11-20 2006-09-26 Dmetrix, Inc. Multi-spectral miniature microscope array
IL155666A (en) * 2003-04-29 2013-12-31 Neurim Pharma 1991 Insomnia treatment

Also Published As

Publication number Publication date
CN1787820A (zh) 2006-06-14
WO2004096118A2 (en) 2004-11-11
ES2380364T3 (es) 2012-05-11
HK1087635A1 (en) 2006-10-20
BRPI0409935A (pt) 2006-04-25
UY28296A1 (es) 2004-11-30
US8859593B2 (en) 2014-10-14
JP4981440B2 (ja) 2012-07-18
ZA200509508B (en) 2006-11-29
PT1620058E (pt) 2012-04-13
EP1620058A2 (de) 2006-02-01
DK1620058T3 (da) 2012-05-07
SI1620058T1 (sl) 2012-05-31
MXPA05011590A (es) 2006-03-08
CL2004000877A1 (es) 2005-01-07
EP1620058B1 (de) 2012-01-04
TW200501948A (en) 2005-01-16
US20140378512A1 (en) 2014-12-25
KR20060005402A (ko) 2006-01-17
JP2012116859A (ja) 2012-06-21
IL155666A (en) 2013-12-31
WO2004096118B1 (en) 2005-12-01
CN1787820B (zh) 2010-05-05
IL155666A0 (en) 2004-09-27
WO2004096118A3 (en) 2005-10-13
NO20055531L (no) 2005-11-23
CA2521182A1 (en) 2004-11-11
NO333015B1 (no) 2013-02-18
TWI340037B (en) 2011-04-11
EP1620058A4 (de) 2006-07-26
NZ542724A (en) 2007-05-31
JP2006525317A (ja) 2006-11-09
CY1112689T1 (el) 2016-02-10
US20060229340A1 (en) 2006-10-12
PE20050144A1 (es) 2005-05-12
AR048370A1 (es) 2006-04-26
CA2521182C (en) 2011-05-31
KR101136885B1 (ko) 2012-04-20
UA87980C2 (ru) 2009-09-10
EA200501666A1 (ru) 2006-06-30
PL1620058T3 (pl) 2012-07-31
EA008768B1 (ru) 2007-08-31
IS8090A (is) 2005-10-25

Similar Documents

Publication Publication Date Title
DE602004005753D1 (de) Kombinationen von harzzusammensetzungen und verwendungsverfahren dafür
DE60238576D1 (de) Zusammensetzung zur Herstellung von Elektroden und Elektroden
DE60331343D1 (de) Zusammensetzungen und verfahren zur veränderung des tocotrienolgehalts
DE60205817D1 (de) Verfahren zur Erfassung und Beseitigung des Memory-Effektes
HK1087635A1 (en) Composition for improving cognition and memory
ATE435859T1 (de) Gyraseinhibitoren und deren verwendungen
DE60317699D1 (de) Fermentationsverfahren und -zusammensetzungen
DE602005017924D1 (de) Zellgewebe-mikrochip und verfahren zur bildung von zellgewebe
DE602004015813D1 (de) Speichervorrichtung und verfahren zur löschung derselben
DE60321130D1 (de) Variation von parametern zur neurostimulation
DE122009000025I1 (de) Antikörper gegen il-12, zusammensetzungen, verfahren und verwendungen
DE60300734D1 (de) Anordnungen zur Vorbehandlung von Proben
DE602005023325D1 (de) Harzzusammensetzung und formkörper daraus
DE60216254D1 (de) Acrylkautschukzusammensetzung und vulkanisat
DE602004031607D1 (de) Propylenpolymerzusammensetzung und verwendung davon
DE60211740D1 (de) Zusammensetzung zur saatgutbehandlung
DE60321938D1 (de) Zusammensetzung zur schleimvermeidung und verfahren zur schleimvermeidung
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
DE602005012674D1 (de) Nachweiselement und nachweisverfahren
ATE499096T1 (de) Kombination von serotonin-wiederaufnahme-hemmern und agomelatin
DE60330255D1 (de) Thermoplastharzzusammensetzung und formkörper daraus
ITBO20020487A0 (it) Contenitore e metodo per la realizzazione dello stesso
DE60334012D1 (de) Valerolactonverbindungen und parf mzusammensetzung
DE60225446D1 (de) Flammgeschützte zusammensetzung und artikel
DE602005015442D1 (de) Kollagen-polyvinylpyrrolidon zur behandlung von osteoarthritis